

1 **Older age, lack of vaccination and infection with variants other than Omicron associated**
2 **with severity of COVID-19 and in-hospital mortality in Pakistan**

3
4 Muhammad Zain Mushtaq^{1*}, Nosheen Nasir^{1*}, Syed Faisal Mahmood¹, Sara Khan¹, Akbar
5 Kanji², Asghar Nasir², Uzma Bashir Aamir³ and Zahra Hasan^{2#}

6 *Contributed equally

7 ¹ Department of Medicine, The Aga Khan University, Karachi, Pakistan

8 ²Department of Pathology and Laboratory Medicine, The Aga Khan University, Karachi,
9 Pakistan

10 ³World Health Organization, Pakistan

11

12 **#Corresponding author**

13 Zahra Hasan, PhD, Professor, Department of Pathology and Laboratory Medicine, The Aga
14 Khan University, Stadium Road, P.O.Box 3500, Karachi 74800, Pakistan. Email:

15 zahra.hasan@aku.edu

16

17 **Key words**

18 Omicron, COVID-19, vaccinations, severity, Pakistan

19

20

21

22

23

24

25 **Abstract**

26 **Objectives:** We investigated factors associated with COVID-19 disease severity and in-hospital
27 mortality in a low-middle income setting.

28 **Methods:** Records of 197 adult COVID-19 patients admitted to the Aga Khan University
29 Hospital, Karachi between April 2021 and February 2022 were reviewed. Clinical data
30 including, that of SARS-CoV-2 variants was collected.

31 **Results:** The median age of the patients was 55 years and 51.8% were males. 48.2 % of patients
32 had non-severe disease, while 52.8% had severe/critical disease. Hypertension (48%) and
33 diabetes mellitus (41.3%) were most common comorbid conditions. Omicron (55.3%), Beta
34 (14.7%), Alpha (13.7%), Delta (12.7%) and Gamma (3.6%) were identified in patients. The risk
35 of severe disease was higher in those aged above 50 years (OR 5.73; 95% CI [2.45-13.7]) and in
36 diabetics (OR 4.24; 95% CI[1.82-9.85]). Full vaccination (OR 0.25; 95% CI [0.11-0.58]) or
37 infection with Omicron variants (OR 0.42; 95% CI[0.23-0.74]) reduced disease severity. Age >
38 50 (OR 5.07; 95% CI [1.92-13.42]) and presence of myocardial infarction (OR 5.11; 95%
39 CI[1.45-17.93]) was associated with increased mortality, but infection with Omicron (OR 0.22
40 95% CI 0.10-0.53]) reduced risk.

41 **Conclusions:**

42 Vaccination was found to protect against severe COVID-19 regardless of the infecting variant
43 and is recommended especially, in those aged over 50 years and with co-morbid conditions.

44

45

46 **Introduction**

47 COVID-19 (Coronavirus Disease 2019) has been diagnosed in greater than 654 million cases with
48 a global death toll of 6.67 million [1]. Global epidemiology of COVID-19 has varied greatly, with
49 the highest burden of deaths to date observed in the USA, Brazil and India [1]. Low middle-income
50 countries such as Pakistan and those in Sub-Saharan and East Africa have been relatively spared
51 and mortality due to COVID-19 has been comparatively lower or under reported [2].

52 Pakistan has thus far experienced 5 distinct pandemic waves, the first, between March and July
53 2020, the second between October 2020 and January 2021, the third, between March and May
54 2021, the fourth between July and September 2021 and the fifth between December and February
55 2022 [3]. As of December 30 2022, COVID-19 has been diagnosed in 1.58 million cases in
56 Pakistan with the number of deaths nearing 31,000 [1]. Of the COVID-19 cases in Pakistan,
57 591,553 (36%) COVID-19 cases were from Sindh province with 40% reported from the city of
58 Karachi [4]. The case fatality rate (CFR) has been 2% with some regional variations. It is of interest
59 to understand the factors associated with COVID-19 severity in the local context. In an earlier
60 study conducted at our center during the first wave of COVID-19; 30% of patients had severe to
61 critical disease at presentation with age and critical disease (identified by septic shock and
62 multiorgan dysfunction) were independently associated with mortality [5].

63 COVID-19 vaccination was first introduced at the start of 2021 [6] and rolled out in stages based
64 on both access and availability in different populations. As in other parts of the world, this
65 contributed to slowing down the pandemic, controlling both morbidity and mortality from COVID-
66 19 [7].

67 Variants carrying mutations in the spike glycoprotein have been described by the World Health
68 Organization to be variants of concern (VoCs) and include, Alpha (B.1.1.7), Beta (B.1.351),
69 Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) [8]. VoCs exhibit genetic modifications
70 linked to increased transmissibility, more severe disease, reduced efficacy of vaccinations or
71 medical treatment [9]. A study from Canada reported that Alpha, Beta, and Gamma were the main
72 variants causing COVID-19 in 2020 with Alpha being the most prevalent variant [10]. Studies

73 from Brazil and Singapore had reported increased severity of disease in COVID-19 patients with
74 the Gamma variant and Delta variant respectively [11].

75 G, L and S clade SARS-CoV-2 strains were shown to be present in the first wave of COVID-19
76 in Pakistan from March until August 2020 [12]. There was a shift in predominance from Alpha
77 to Delta variants between April and July 2021 and then again from Delta to Omicron variants
78 between December and February 2022 [13]. The Omicron variant which emerged in the latter
79 half of 2021, had more than 50 mutations across the genome, resulting in reduced vaccine
80 efficacy with a greater chance of breakthrough infections [14]. Omicron was found to be more
81 transmissible compared with other variants, with a greater chance of re-infections however, with
82 a reduction in hospital associated mortality [15].

83 Throughout the pandemic, COVID-19 related mortality in Pakistan remained low when compared
84 to the other countries [16]. However, the clinical outcomes of patients with severe COVID-19
85 related to the infecting variants remain to be elucidated. We, therefore, assessed the risk factors,
86 clinical presentation and outcomes in relation to the VoC in patients with COVID-19 in Karachi,
87 Pakistan.

88 **Methods**

89 This was a retrospective cohort study of adults with a PCR confirmed COVID-19 patients admitted
90 to the Aga Khan University Hospital (a 700-bedded tertiary care hospital in Karachi, Pakistan),
91 between April 2021 and February 2022.

92 All COVID-19 cases had a SARS-CoV-2 PCR positive respiratory sample using the SARS-CoV-
93 2 Cobas 6800 Roche assay, at the AKUH Clinical Laboratories, Karachi, Pakistan. The CT
94 (crossing threshold) value of each positive SARS-CoV-2 sample was noted. The cases chosen for
95 review were those for whom SARS-CoV-2 VoC testing had been conducted as part of a World
96 Health Organization supported ongoing genomic surveillance effort [17].

97 Data was collected on symptoms at presentation, treatment, duration of illness, outcomes and also,
98 COVID-19 vaccination. Laboratory and radiological data were collected for all cases. COVID-19
99 severity was categorized into non-severe in patients who have oxygen saturation $\geq 94\%$ on room
100 air, severe in those who have an oxygen saturation of $< 94\%$ and require supplemental oxygen

101 support and critical in those who have respiratory failure, shock and/or multiorgan dysfunction
102 [18]. WHO ordinal score for the severity of COVID-19 [19], length of hospital stay and in-hospital
103 mortality were also recorded. Individuals who had received both doses of a two-dose vaccine
104 regimen were categorized as ‘Fully vaccinated’, those who had received one dose of a two-dose
105 vaccine regimen were categorized as ‘Partially vaccinated’ and those who had not yet received a
106 single dose of COVID-19 vaccination were classified as ‘Unvaccinated’.

107 **Identification of VoC**

108 Isolates were screened for VoC; Alpha, Beta, Gamma, Delta and Omicron lineage associated
109 mutations using a PCR-based approach [13].

110 **Statistical Analysis**

111 Median and interquartile range was reported for continuous variables such as age and length of
112 stay and frequency and percentages were used to describe categorical variables such as gender and
113 mortality. Comparison between categorical variables was determined using Chi-square test or
114 Fischer exact test where appropriate. P-value of < 0.05 was considered significant. Logistic
115 regression analysis was performed to examine the effect of each exposure variable on the severity
116 of illness and in-hospital mortality and adjusted Odds ratios (OR) and their 95% confidence
117 intervals (CI) were estimated. Data was analyzed using STATA version 12.0.

118

119 **Results**

120 **Description of COVID-19 cases**

121 We studied the clinical characteristics and disease outcomes of $n=197$ COVID-19 patients
122 admitted at AKUH between April 2021 and February 2022, to investigate the relationship between
123 disease outcomes and SARS-CoV-2 infecting variants. Three COVID-19 waves were observed in
124 Pakistan during this study period (Supplementary Figure 1A). COVID-19 mortality was observed
125 to be lower in the period between December 2021 and February 2022, as compared with the earlier
126 two waves (Supplementary Figure 1B). Notably, cases in April 2021 were mostly associated with
127 Alpha variants whilst those in July and August 2021 were associated with the Delta wave in
128 Pakistan [20].

129 The median age of the patients was 55 years (IQR 34-70 years) and 51.8% (n=102) were males,
130 Supplementary Table 1. Hypertension (48%) and diabetes (41.3%) were the most common
131 comorbid conditions. There were 23 pregnant patients (24.2% of females) and most of them were
132 identified on screening before delivery. Amongst the pregnant women, 8 (34.7%) developed
133 obstetric complications including intrauterine fetal demise in two cases.

134 Upon admission, 48.2 % of patients had non-severe disease, while 51.8% had severe/critical
135 disease. Fifty percent of patients had received systemic corticosteroids. Most patients survived
136 (70.6%) till the time of discharge while 38 (19.3%) patients died and 20 (10.2 %) left against
137 medical advice (Supplementary Table 1). Vaccination data was available for 154 patients. 46.7%
138 of study subjects were unvaccinated and 30 % were vaccinated, of which all but three individuals
139 were fully vaccinated. Complications occurred in 27.4% patients (Supplementary Table 1). The
140 most frequent complication was acute kidney injury in 14.7%, followed by myocardial infarction
141 in 9.1% and pneumothorax/pneumomediastinum in 3.6% patients.

142 The Omicron variant was found in 55.3% of patients, with Alpha variants in 13.7%, Beta in 14.7%
143 and Delta in 12.7% of cases. As these were in a relatively smaller number compared with Omicron,
144 we combined cases with Alpha, Beta, Delta and Gamma variants into a non-Omicron group for
145 further comparative analysis.

146 Vaccination data were available for 154 out of 197 patients. 46.7% of patients were unvaccinated
147 and 30 % were fully-vaccinated, and 1.5% were partially-vaccinated.

148

149 **Factors associated with severe COVID-19**

150 We investigated the factors associated with severe COVID-19 by stratifying the study group into
151 those with non-severe as compared with severe/critical disease. Age, clinical characteristics,
152 vaccination status and infecting SARS-CoV-2 variants were all compared between the two sub-
153 groups. Most patients who developed severe disease were older than 50 years ($p < 0.001$) and were
154 12 ($p < 0.001$) or discharged ($p < 0.001$) and increased length of hospital stay ($p < 0.001$). Vaccination
155 (OR 0.45; 95% CI[0.23-0.88]), $p < 0.001$ was associated with non-severe disease. Infection with
156 the Omicron variant was associated with non-severe disease (OR 0.42; 95% CI[0.23-0.74]),
157 $p = 0.003$.

158 In a multivariate analysis, the independent risk factors for severe/critical disease were found to be
159 age greater than or equal 50 years of (aOR 5.73; 95% CI[2.45-13.7]) and presence of diabetes
160 mellitus (aOR 4.24; 95% CI[1.82-9.85]) whereas being fully vaccinated (aOR 0.25; 95% CI[0.11-
161 0.58]) were found to be protective against severe/critical disease (Table 2).

162

163 **Factors associated with mortality**

164 Factors associated with in-hospital mortality in our COVID-19 patient cohort were determined
165 (after excluding 20 patients who left against medical advice, Supplementary Table 1). The median
166 age of those who died was 64 years whilst those who survived was 48 years, Table 3. A univariate
167 analysis showed age greater than or equal to 50 years (OR=5.73; (95% CI: 2.25-14.6), p=0.001;
168 the presence of co-infections or secondary infections (OR:2.45; 95%CI:1.08-5.58), p=0.032,
169 presence of complications such as myocardial infarction (MI) (OR:5.03; 95% CI: 1.69-14.9),
170 p=0.004, acute kidney injury (AKI) (OR:3.78; 95%CI: 1.48-9.61), p=0.005, having pneumothorax
171 or pneumomediastinum (OR:8.05; 95%CI:1.42-45.8), p=0.019 and being unvaccinated (OR: 2.94;
172 95% CI:1.02-8.39), p=0.044, all to associated with greater risk of death. Infection with Omicron
173 as compared with non-Omicron variants was associated with survival (OR:0.28; 95%CI: 0.13-
174 0.61), p=0.001.

175 A multivariate analysis run after adjusting for confounding and effect modification from other
176 variables further confirmed in-hospital mortality were found to be associated with age greater than
177 50 years (aOR 5.07; 95% CI [1.92-13.42]), p=0.001, and the presence of MI (aOR 5.11; 95%
178 CI[1.45-17.93]), p=0.001. Infection with the Omicron variant was associated with survival (aOR:
179 0.22; 95% CI: 0.10-0.53), p=0.001.

180

181 **Viral loads were higher in Omicron infected individuals**

182 Higher SARS-CoV-2 viral loads have been associated with more severe disease. We determined
183 the viral loads present in respiratory specimens and analysed them according to the VoC. The CT
184 of SARS-CoV-2 target gene amplification was used as a marker of viral loads. We found a
185 significant difference between the CT values of the VoC, Figure 1, p=0.015, Kruskal-Wallis

186 analysis. In particular, the CT values of Omicron variants were lower, reflecting significantly
187 higher viral loads as compared with the Alpha variant, $p=0.0005$.

188

189 **Discussion**

190 We conducted a hospital-based analysis of the association of SARS-CoV-2 VoC with clinical
191 outcomes in patients with COVID-19 from Karachi, Pakistan between April 2021 to February
192 2022. Diabetes mellitus, hypertension, chronic kidney disease, age over 50 years, and critical
193 disease on presentation were associated with higher mortality. In our cohort, a large proportion of
194 patients were unvaccinated and nearly half developed critical disease. Furthermore, it was noted
195 that infection caused by the omicron variant was associated with significantly lower risk of severe
196 disease at presentation as well as reduced mortality rates.

197 Omicron variant wave peaked in January 2022 in Pakistan and it was related to highest number of
198 cases since the beginning of the pandemic [1, 21]. In many European countries, the case fatality
199 rate from infections with the Omicron variant was significantly lower as compared with Delta,
200 despite the higher rate of new infections [22]. The period between April and December 2021, was
201 dominated by the Alpha variant then followed by the emergence of the Beta variant in May and
202 the Delta variant in July 2021 [23]. A population based study from UK reported an increase in
203 deaths due to Alpha variants from 2.5 to 4.1 per 1000 detected cases [24].

204 During the first year of the pandemic (2020) in Karachi, we had observed that severe to critical
205 disease at presentation, and age more than 60 years and critical disease to be independently
206 associated with mortality[5]. This trend remained consistent in 2021 and 2022 except, that patients
207 infected with Omicron variant had lesser odds of dying of COVID-19 as compared with non-
208 Omicron variants, matching previous reports [25]. This fits with reports from South Africa that
209 showed the Omicron wave had a reduced COVID-19 related mortality in patients aged 50 years
210 and above [26].

211 The majority of our vaccinated study subjects were infected with the Omicron variant likely due
212 to surge in January 2022, and the higher risk of breakthrough infections seen with this variant.
213 Importantly, the Omicron variant had lower CT values associated with higher viral loads as
214 compared with the Alpha variant. This differs from previous variants where genome-wise analysis

215 of SARS-CoV-2 have demonstrated higher viral loads to be associated with increased disease
216 severity [27].

217 Recent reports show that Omicron variant caused less severe disease across multiple countries in
218 the context of different kinds of COVID-19 vaccinations [15]. In our study, vaccinated individuals
219 were found to have a reduced risk of mortality from COVID-19. This matches previous reports
220 which have shown effectiveness of COVID-19 vaccines in protection against severe disease [7,
221 28].

222 A limitation of our study that it is from a single-center tertiary care facility. Further, our sample
223 size was relatively small and we did not have complete vaccination details for all study subjects.
224 Unfortunately, we were unable to collection information regarding vaccination from all cases.
225 During the study period, the most frequently administered vaccines in Pakistan were, BBIBP-CorV
226 (Sinopharm), SinoVac and CanSinoBio. It has been shown that BBIBP-CorV vaccination was
227 protective against severe COVID-19 in Pakistan during the Delta wave [29]. An efficacy study of
228 different vaccines used in Pakistan has shown that inactivated virus type of vaccinations were
229 moderately effective against symptomatic COVID-19, less effective than mRNA vaccination [30].
230 We were unable to obtain information on the vaccination type from all subjects therefore, our study
231 cannot provide insights on the impact of any specific COVID-19 vaccine. However, this provides
232 key information as to the impact of VoC and its impact on severity of illness and mortality in
233 hospitalized patients with COVID-19 in Pakistan.

234 In summary, we describe the pattern of SARS-CoV-2 VoCs present in the hospitalized population
235 of COVID-19 cases over the second, third and fourth waves in Pakistan, from April 2021 until
236 February 2022. We observed reduced disease severity and mortality due to the Omicron variant
237 as compared with non-Omicron VoCs. Our findings are in accordance with the trends seen in
238 national data for morbidity and mortality due to COVID-19. Finally, our data reveals that the
239 introduction of VoCs was associated with successive COVID-19 waves. However, presence of
240 Omicron was associated with reduced likelihood of death in our patient population.

241

242 **Ethics Statement**

243 This work complies with the policies for Ethical Consent as per Helsinki Declaration. The work
244 received approval from the Ethical Review Committee of the Aga Khan University (study
245 reference no. 2021-6232-19404).

246 **Acknowledgements**

247 Funding for SARS-CoV-2 variant testing was supported by the World Health Organization,
248 Pakistan and through a COVID-19 Research Rapid Grant from the Higher Education Commission,
249 Pakistan.

250 **Authorship Contributions**

251 The study was designed and supervised by ZH. MZM and NN contributed equally in data analysis
252 and preparation of the manuscript draft. SK, SFM, MZM and NN collected and analysed data. AK
253 and AN conducted the laboratory testing and data analysis. ZH and UBA secured funding for the
254 study. All authors have approved the manuscript submission.

255 **Contributions**

256 Thanks to Azra Samreen and Ali Raza Bukhari for their technical assistance. Thanks to M Asif
257 Syed and Mansoor Wassan, Department of Health, Sindh, for facilitation with COVID-19
258 vaccination data.

259

260 **References**

- 261 1. JHU, *COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at*
262 *Johns Hopkins University. 28 February 2022.*
- 263 2. Maeda, J.M. and J.N. Nkengasong, *The puzzle of the COVID-19 pandemic in Africa. Science, 2021.*
264 **371**(6524): p. 27-28.
- 265 3. Pakistan, G.o. *COVID-19 Health Advisory Platform. Ministry of National Health Services*
266 *Regulations and Coordination. . 2021 31 July 2021]; Available from: <https://covid.gov.pk/>.*
267 4. Department, H. *Daily Situation Report. 2022 30 December 2022].*
- 268 5. Nasir, N., et al., *Clinical characteristics and outcomes of COVID-19: Experience at a major tertiary*
269 *care center in Pakistan. J Infect Dev Ctries, 2021. 15*(4): p. 480-489.
- 270 6. *Pakistan receives first consignment of COVID-19 vaccines via COVAX Facility. 2021, EMRO, WHO:*
271 [http://www.emro.who.int/media/news/pakistan-receives-first-consignment-of-covid-19-](http://www.emro.who.int/media/news/pakistan-receives-first-consignment-of-covid-19-vaccines-via-covax-facility.html)
272 [vaccines-via-covax-facility.html](http://www.emro.who.int/media/news/pakistan-receives-first-consignment-of-covid-19-vaccines-via-covax-facility.html).
- 273 7. Chen, X., et al., *Impact of vaccination on the COVID-19 pandemic in U.S. states. Sci Rep, 2022.*
274 **12**(1): p. 1554.

- 275 8. WHO. *Tracking SARS-CoV-2 variants*. 23rd September, 2021; Available from:
276 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>.
- 277 9. Zeyaulah, M., et al., *COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health*
278 *Concern*. *Front Genet*, 2021. **12**: p. 693916.
- 279 10. Tuite, A., et al., *COVID-19 hospitalizations, ICU admissions and deaths associated with the new*
280 *variants of concern*. *Sci Briefs Ont COVID-19 Sci Advis Table*, 2021. **1**: p. 18.
- 281 11. Nonaka, C.K.V., et al., *SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and*
282 *middle-aged patients admitted to the intensive care units of a single hospital in Salvador,*
283 *northeast Brazil, February 2021*. *Int J Infect Dis*, 2021.
- 284 12. Ghanchi, N.K., et al., *Higher entropy observed in SAR-CoV-2 genomes from the first COVID-19*
285 *wave in Pakistan* *PLoS ONE*, 2021. **16(8)**(e0256451): p.
286 <https://doi.org/10.1371/journal.pone.0256451>.
- 287 13. Nasir, A., et al. *SARS-CoV-2 Variants of Concern (VOC) Alpha, Beta, Gamma, Delta, and*
288 *Omicron coincident with consecutive pandemic waves in Pakistan*. medRxiv, 2022.
- 289 14. Iketani, S., et al., *Antibody evasion properties of SARS-CoV-2 Omicron sublineages*. *Nature*, 2022.
- 290 15. Beraud, G., et al., *Impact of vaccination on the presence and severity of symptoms of*
291 *hospitalised patients with an infection by the omicron variant (B.1.1.529) of the SARS-cov-2*
292 *(subvariant BA.1)*. *Clinical Microbiology and Infection*.
- 293 16. Edouard Mathieu, H.R., Lucas Rodés-Guirao, Cameron Appel, Daniel Gavrilov, Charlie Giattino,
294 Joe Hasell, Bobbie Macdonald, Saloni Dattani, Diana Beltekian, Esteban Ortiz-Ospina, and Max
295 Roser, *Coronavirus Pandemic (COVID-19)*. *Our World in Data*, 2020.
- 296 17. Zahra, H., et al., *Changing SARS-CoV-2 variants in Karachi, Pakistan from alpha to delta through*
297 *COVID-19 waves three and four*. *Research Square*, 2021.
- 298 18. NIH, U. *Clinical Spectrum of SARS-CoV-2 Infection*. *COVID-19 Treatment Guidelines 2022*
299 *September 26, 2022*].
- 300 19. WHO, *novel Coronavirus COVID-19 Therapeutic Trial Synopsis*, in *R&D Blueprint*. 2020.
- 301 20. Hasan, Z., et al., *Changing SARS-CoV-2 variants in Karachi, Pakistan from alpha to delta through*
302 *COVID-19 waves three and four*. *Research Square*. doi.10.21203/rs.3.rs-828919/v1 2021.
- 303 21. Umair, M., et al., *Tracking down B.1.351 SARS-CoV-2 variant in Pakistan through genomic*
304 *surveillance*. *J Med Virol*, 2022. **94(1)**: p. 32-34.
- 305 22. Nyberg, T., et al., *Comparative analysis of the risks of hospitalisation and death associated with*
306 *SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study*.
307 *Lancet*, 2022. **399(10332)**: p. 1303-1312.
- 308 23. Umair, M., Ikram, A., Salman, M., Haider, S.A., Badar, N., Rehman, Z., Ammar, M., Rana, M.S.
309 and Ali, Q, *Genomic surveillance reveals the detection of SARS-CoV-2 delta, beta, and gamma*
310 *VOCs during the third wave in Pakistan*. *Journal of Medical Virology*, 2022. **94(3)**: p. 1115-1129.
- 311 24. Challen, R., et al., *Risk of mortality in patients infected with SARS-CoV-2 variant of concern*
312 *202012/1: matched cohort study*. *BMJ*, 2021. **372**: p. n579.
- 313 25. Reichert, E., et al., *Methods for early characterisation of the severity and dynamics of SARS-CoV-*
314 *2 variants: a population-based time series analysis in South Africa*. *The Lancet Microbe*, 2022.
315 **3(10)**: p. e753-e761.
- 316 26. Wolter, N., et al., *Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in*
317 *South Africa: a data linkage study*. *Lancet*, 2022. **399(10323)**: p. 437-446.
- 318 27. Skarzynski, M., et al., *SARS-CoV-2 Genome-Based Severity Predictions Correspond to Lower qPCR*
319 *Values and Higher Viral Load*. *Glob Health Epidemiol Genom*, 2022. **2022**: p. 6499217.
- 320 28. Hall, V., et al., *Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection*.
321 *N Engl J Med*, 2022. **386(13)**: p. 1207-1220.

- 322 29. Nadeem, I., et al., *Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of*
323 *Faisalabad district of Pakistan*. Postgrad Med J, 2022.
- 324 30. Nisar, M.I., et al., *Assessing the effectiveness of COVID-19 vaccines in Pakistan: a test-negative*
325 *case-control study*. J Infect, 2023.
- 326
- 327

328 **Table 1. Clinical characteristics associated with non-severe as compared with**
 329 **severe/critical COVID-19**

Variables	Non-severe (n=95)	Severe/critical (n=102)	Unadjusted OR (95% CI)	p-value
Age Range (years)				
<50	60 (63.2)	22 (21.6)	(Ref)	<0.001
>=50	35 (36.8)	80 (78.4)	6.23 (3.32- 11.7)	
Median (IQR)	37 (28-60)	65 (50-74)	1.05 (1.03- 1.07)	<0.001
Gender	n (%)	n (%)		
Male	41 (43.2)	61 (59.8)	(Ref)	0.019
Female	54 (56.8)	41 (40.2)	0.51 (0.30- 0.90)	
Pregnant	20 (37.0)	3 (7.3)	0.13 (0.37- 0.49)	0.001
Co-morbid conditions				
DM	21 (22.1)	60 (58.8)	5.03 (2.69 – 9.40)	<0.001
HTN	30 (31.6)	64 (62.8)	3.65 (2.02- 6.58)	<0.001
IHD	10 (10.5)	29 (28.4)	3.38 (1.54- 7.39)	0.002
CKD	2 (2.1)	18 (17.7)	9.96 (2.24- 44.2)	<0.001
WHO Ordinal score	Median (IQR)	Median (IQR)		
At admission	3 (1-4)	5 (5-6)	8.02 (4.38- 14.69)	<0.001
At discharge	1 (1-2)	3 (2-8)	7.52 (3.42- 16.54)	<0.001
LOS	1 (1-3)	7 (3-15)	1.18 (1.10- 1.27)	<0.001
Outcome at discharge	n (%)	n (%)		<0.001
Dead	1 (1.05)	37 (36.3)	70.1 (9.3 - 527.09)	
Alive	91 (95.8)	48 (47.0)	Ref	
LAMA	3 (3.2)	17 (16.7)		

Vaccination status	n (%)	n (%)		
Unvaccinated	38 (40.0)	54(52.9)	Ref	
Fully vaccinated	36 (37.9)	23 (22.5)	0.45 (0.23 – 0.88)	0.019
VoC	n (%)	n (%)		
Non-Omicron	32 (33.7)	56 (54.9)	Ref	
Omicron	63 (66.3)	46 (45.1)	0.42 (0.23 – 0.74)	0.003

330

331 DM: Diabetes Mellitus, HTN: Hypertension, IHD: ischemic heart disease, CKD: chronic kidney
332 disease, LOS: length of stay, IQR: interquartile range, LAMA: left against medical advice, MI:
333 myocardial infarction, AKI: acute kidney injury, VoC: variant of concern, Non-Omicron include
334 Alpha, Beta, Delta and Gamma variants.

335

336

337

338

339

340

341

342

343 **Table 2. Factors associated with COVID-19 severity**

Severity of illness	Adjusted Odds Ratio	(95% Confidence Interval)	p-value
Age >= 50	5.73	(2.45-13.7)	<0.001
Presence of Diabetes Mellitus	4.24	(1.82-9.85)	0.001
Fully Vaccinated	0.25	(0.11-0.58)	0.001

344

345 A multivariable model was run to investigate factors associated with severity of illness using
346 STATA software

347

348

349 **Table 3: Clinical characteristics of COVID-19 patients associated with mortality**

Variables	Died (n=38)	Alive (n=139)	Unadjusted OR (95% CI)	p-value	Multivariate analysis OR (95% CI)	p-value
Age Range n (%)						
18-29	1 (2.6)	32 (23.0)	(Ref)			
30-49	5 (13.2)	40 (28.8)	4.0 (0.4-35.9)	0.219		
50-69	16 (42.1)	35 (25.2)	14.6 (1.83-116.6)	0.011		
>=70	16 (42.1)	32 (23.0)	16.0 (2.0-127.9)	0.009		
Age						
<50	6 (15.8)	72 (51.8)	Ref			
>=50	32 (84.2)	67 (38.2)	5.73 (2.25-14.6)	<0.001	5.07(1.92-13.42)	0.001
Median Age (IQR) years	64 (55-75)	48 (30-69)	1.04 (1.02-1.06)	0.001		
Gender n (%)						
Male	22 (57.9)	66 (47.5)	(Ref)			
Female	16 (42.1)	73 (52.5)	0.66 (0.32-1.36)	0.257		
Co-morbids n (%)						
DM	20 (52.6)	49 (35.2)	2.04 (0.99 - 4.22)	0.054		
HTN	22 (57.9)	59 (42.5)	1.86 (0.90-3.86)	0.093		
IHD	10 (26.3)	22 (15.8)	1.90 (0.80-4.46)	0.141		
CKD	4 (10.5)	10 (7.2)	1.52 (0.45-5.14)	0.503		
Co-infection or secondary infections n (%)	12 (31.6)	22 (15.8)	2.45 (1.08-5.58)	0.032		
Complications n (%)						
MI	8 (21.1)	7 (5.0)	5.03 (1.69-14.9)	0.004	5.11(1.45-17.93)	0.001
AKI	10 (26.3)	12 (8.6)	3.78 (1.48-9.61)	0.005		
Pneumothorax/pneumomed	4 (10.5)	2 (1.2)	8.05 (1.42-45.8)	0.019		

Laboratory parameters						
At Day 1						
CRP (mg/L)<100 (Ref)	17 (44.7)	59 (42.4)	Ref			
CRP >=100	21 (55.3)	80 (57.6)	0.91 (0.44-1.87)	0.80		
D-Dimer (mg/L)<1.5 (Ref)	7 (18.4)	40 (28.8)	Ref			
D-Dimer >1.5	31 (81.6)	99 (71.2)	1.78 (0.72-4.39)	0.204		
Vaccination status*						
Fully vaccinated	5 (13.1)	47 (33.8)	Ref			
Unvaccinated	20 (52.6)	64 (46.0)	2.94(1.02-8.39)	0.044		
VoC n (%)						
alpha	7 (18.4)	17 (12.2)	(Ref)			
beta	8 (21.0)	18 (12.9)	1.07 (0.32-0.62)	0.902		
gamma	3 (7.8)	3 (2.2)	2.42 (0.39 - 15.0)	0.641		
delta	8 (21.0)	15 (10.8)	1.29 (0.38 - 4.43)	0.680		
Omicron	12 (31.6)	86 (61.9)	0.34 (0.12 - 0.98)	0.047		
VoCs	n (%)	n (%)				
Non-Omicron	26 (68.4)	53 (38.1)	Ref			
Omicron	12 (31.6)	86 (61.9)	0.28(0.13-0.61)	0.001	0.22(0.10-0.53)	0.001

350

351 DM: Diabetes Mellitus, HTN: Hypertension, IHD: ischemic heart disease, CKD: chronic kidney
 352 disease, LOS: length of stay, IQR: interquartile range, MI: myocardial infarction, AKI: acute
 353 kidney injury, CRP: C - reactive protein.

354 *20 patients who left against medical advice and 3 patients who were partially vaccinated were
 355 excluded.

356

357

358 **Figure Legends**

359

360 **Figure 1. SARS-CoV-2 Omicron variants have lower CT values.** The amplification thresholds
361 (CT values) of the infecting VoC in SARS-CoV-2 positive nasal specimens of 197 patients was
362 analysed according to the variant type. The graph depicts data for alpha (n=27), beta (n=29),
363 gamma (n=7), delta (n=25) and omicron (n=109) variants. Data shown is for the Orf1ab gene is
364 depicted as per the SARS-CoV-2 Cobas 6800 Roche assay. The horizontal lines depict the median
365 values for each group. The scatter plots depict interquartile ranges (10-90th percentile) for each
366 group. MWU analysis, with 95% significance $p < 0.05$

367

